Abstract
In the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial, tafamidis significantly reduced all-cause mortality and cardiovascular-related hospitalizations in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM is associated with a significant burden of disease; further analysis of patient-reported quality of life will provide additional data on the efficacy of tafamidis. In the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial, 441 adult patients with ATTR-CM were randomized (2:1:2) to tafamidis 80 mg, tafamidis 20 mg, or placebo for 30 months, with pooled tafamidis (80 mg and 20 mg) compared with placebo. Change in Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) domain scores, EQ-5D-3L scores, and patient global assessment, were prespecified exploratory end points. A greater proportion of patients improved KCCQ-OS score at month 30 with tafamidis (41.8%) versus placebo (21.4%). Tafamidis significantly reduced the decline in all 4 KCCQ-OS domains (p <0.0001 for all), and in EQ-5D-3L utility (0.09 [confidence interval 0.05 to 0.12]; p <0.0001) and EQ visual analog scale (9.11 [confidence interval 5.39 to 12.83]; p <0.0001) scores at month 30 versus placebo. A larger proportion of...Continue Reading
References
Nov 5, 1990·Health Policy·UNKNOWN EuroQol Group
Apr 12, 2000·Journal of the American College of Cardiology·C P GreenJ A Spertus
Feb 24, 2005·Medical Care·James W ShawStephen Joel Coons
Sep 28, 2005·Circulation·Rodney H Falk
Oct 8, 2005·American Heart Journal·John SpertusUNKNOWN Cardiovascular Outcomes Research Consortium
Feb 21, 2006·Journal of the American College of Cardiology·Paul A HeidenreichUNKNOWN Cardiovascular Outcomes Research Consortium
Apr 11, 2007·Circulation·Mikhail KosiborodJohn A Spertus
Sep 16, 2009·Circulation·Claudio RapezziStefano Perlini
Oct 15, 2009·American Heart Journal·Kathryn E FlynnUNKNOWN HF-ACTION Investigators
Dec 17, 2011·American Heart Journal·Kathryn E FlynnKevin P Weinfurt
Sep 6, 2012·Circulation·Frederick L Ruberg, John L Berk
Nov 28, 2015·Journal of the American College of Cardiology·Morie A GertzGiampaolo Merlini
Jul 9, 2016·Journal of the American College of Cardiology·Mathew S MaurerUNKNOWN THAOS Investigators
Mar 23, 2017·European Heart Journal·Esther González-LópezPablo Garcia-Pavia
Jun 15, 2017·Circulation. Heart Failure·Mathew S MaurerUNKNOWN ATTR-ACT Study Investigators
Aug 4, 2018·Neurology and Therapy·Michelle StewartWilliam R Lenderking
Aug 28, 2018·The New England Journal of Medicine·Mathew S MaurerUNKNOWN ATTR-ACT Study Investigators
Apr 3, 2019·European Heart Journal·Thibaud DamyUNKNOWN THAOS Investigators
May 17, 2019·Muscle & Nerve·Aaron YarlasSpencer D Guthrie
May 22, 2019·Circulation·Thirusha LaneJulian D Gillmore
Jun 7, 2019·Journal of the American College of Cardiology·Frederick L RubergMathew S Maurer